Supplementary Information

Table S1. Search Formulas and Results in Each Database

Database	Search Formula	Results
Cochrane Library	("Idiopathic Pulmonary Fibrosis" OR IPF):ti,ab,kw AND (pirfenidone OR nintedanib OR "BI 1015550" OR nerandomilast OR antifibrotic):ti,ab,kw AND ("randomized controlled trial" OR RCT OR randomised):ti,ab,kw	570
Embase	('idiopathic pulmonary fibrosis'/exp OR 'idiopathic pulmonary fibrosis' OR IPF) AND (pirfenidone OR nintedanib OR "BI 1015550" OR nerandomilast OR antifibrotic) AND ('randomized controlled trial'/exp OR RCT OR randomised)	933
PubMed	(((Idiopathic Pulmonary Fibrosis) OR IPF) AND (pirfenidone OR nintedanib OR "BI 1015550" OR nerandomilast OR antifibrotic)) AND (randomized controlled trial OR RCT OR randomised)	396
Web of Science	TS=("Idiopathic Pulmonary Fibrosis" OR IPF) AND TS=(pirfenidone OR nintedanib OR "BI 1015550" OR nerandomilast OR antifibrotic) AND TS=("randomized controlled trial" OR RCT OR randomised)	386

Figure S1. PRISMA Flowchart of Study Screening



Figure S2. Ranking Probabilities of Treatments for FVC Decline



The tallest bar for each treatment indicates the most probable rank.

NRD-L: Nerandomilast low dose; NRD-HN: Nerandomilast high dose with Nintedanib; NRD-H: Nerandomilast high dose; NRD-HP: Nerandomilast high dose with Pirfenidone.; NRD-LN: Nerandomilast high dose with Nintedanib; NRD-LP: Nerandomilast low dose with Pirfenidone

Figure S3. Direct and Indirect Comparisons of Treatments for FVC



Figure S4. Network Graph of Included Studies on All-Cause Mortality



Figure S5. Ranking of Treatments by All-Cause Mortality



The tallest bar for each treatment indicates the most probable rank.

Figure S6. Network Graph of Included Studies on Serious Adverse Events



Figure S7. Ranking of Treatments by Serious Adverse Events



The tallest bar for each treatment indicates the most probable rank.

Figure S8. Summary of Risk of Bias Assessment